Amrut Ambardekar
Concepts (438)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 39 | 2026 | 567 | 7.990 |
Why?
| | Heart Failure | 55 | 2026 | 2314 | 6.040 |
Why?
| | Heart Transplantation | 25 | 2025 | 736 | 4.670 |
Why?
| | Cardiomyopathies | 15 | 2026 | 337 | 3.260 |
Why?
| | Amyloid Neuropathies, Familial | 8 | 2026 | 24 | 2.530 |
Why?
| | Amyloidosis | 4 | 2023 | 44 | 1.700 |
Why?
| | Heart Ventricles | 9 | 2020 | 756 | 1.520 |
Why?
| | Prealbumin | 8 | 2026 | 36 | 1.500 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 359 | 1.060 |
Why?
| | Myocardium | 11 | 2026 | 939 | 1.050 |
Why?
| | Myocytes, Cardiac | 14 | 2026 | 551 | 1.010 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 390 | 1.000 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 145 | 0.910 |
Why?
| | Humans | 111 | 2026 | 144261 | 0.820 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 360 | 0.800 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 248 | 0.780 |
Why?
| | Graft Rejection | 4 | 2025 | 540 | 0.750 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.740 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 382 | 0.740 |
Why?
| | Assisted Circulation | 2 | 2021 | 26 | 0.720 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 43 | 0.710 |
Why?
| | Fibrosis | 5 | 2022 | 547 | 0.700 |
Why?
| | Transplant Recipients | 4 | 2021 | 180 | 0.700 |
Why?
| | Echocardiography | 7 | 2017 | 647 | 0.690 |
Why?
| | Vascular Stiffness | 2 | 2017 | 462 | 0.680 |
Why?
| | Hemodynamics | 7 | 2023 | 1119 | 0.670 |
Why?
| | Stroke Volume | 9 | 2024 | 648 | 0.670 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 69 | 0.660 |
Why?
| | Giant Cells | 1 | 2020 | 21 | 0.660 |
Why?
| | Middle Aged | 42 | 2026 | 35762 | 0.650 |
Why?
| | Arteries | 1 | 2022 | 258 | 0.650 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 846 | 0.630 |
Why?
| | Aortic Diseases | 1 | 2021 | 124 | 0.630 |
Why?
| | Heart Neoplasms | 1 | 2020 | 55 | 0.630 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 538 | 0.620 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 83 | 0.620 |
Why?
| | Myocarditis | 1 | 2020 | 102 | 0.600 |
Why?
| | Ventricular Remodeling | 5 | 2026 | 275 | 0.600 |
Why?
| | Coronary Vessels | 2 | 2018 | 251 | 0.590 |
Why?
| | Male | 56 | 2026 | 72035 | 0.580 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 297 | 0.580 |
Why?
| | Myocardial Contraction | 4 | 2020 | 298 | 0.560 |
Why?
| | Brugada Syndrome | 2 | 2009 | 14 | 0.560 |
Why?
| | Heart | 6 | 2023 | 633 | 0.540 |
Why?
| | Female | 54 | 2026 | 77976 | 0.520 |
Why?
| | Aged | 28 | 2026 | 25850 | 0.520 |
Why?
| | Extracellular Matrix | 1 | 2021 | 553 | 0.520 |
Why?
| | Bariatric Surgery | 1 | 2021 | 236 | 0.510 |
Why?
| | Treatment Outcome | 16 | 2026 | 11643 | 0.490 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 284 | 0.490 |
Why?
| | Cryosurgery | 1 | 2016 | 47 | 0.460 |
Why?
| | Heart Rate | 2 | 2021 | 849 | 0.440 |
Why?
| | Thrombosis | 2 | 2016 | 393 | 0.440 |
Why?
| | Benzoic Acid | 4 | 2026 | 9 | 0.420 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 268 | 0.420 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 181 | 0.420 |
Why?
| | Blood Pressure | 5 | 2022 | 1759 | 0.410 |
Why?
| | Marijuana Abuse | 1 | 2016 | 211 | 0.400 |
Why?
| | Electrocardiography | 4 | 2020 | 660 | 0.400 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 286 | 0.370 |
Why?
| | Myofibrils | 3 | 2022 | 49 | 0.370 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 581 | 0.370 |
Why?
| | Patient-Centered Care | 2 | 2021 | 540 | 0.360 |
Why?
| | Recovery of Function | 3 | 2026 | 706 | 0.350 |
Why?
| | Alternative Splicing | 2 | 2026 | 247 | 0.350 |
Why?
| | Adult | 23 | 2026 | 40262 | 0.340 |
Why?
| | Guideline Adherence | 3 | 2011 | 586 | 0.340 |
Why?
| | Patient Compliance | 2 | 2017 | 585 | 0.320 |
Why?
| | Pyrazoles | 4 | 2026 | 509 | 0.310 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 14 | 0.310 |
Why?
| | Cardiology | 2 | 2023 | 353 | 0.310 |
Why?
| | Calcium | 4 | 2023 | 1182 | 0.310 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 177 | 0.310 |
Why?
| | Baroreflex | 2 | 2021 | 57 | 0.300 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 62 | 0.300 |
Why?
| | Risk Assessment | 6 | 2021 | 3637 | 0.300 |
Why?
| | Sarcomeres | 3 | 2022 | 98 | 0.300 |
Why?
| | Hospitals, Rural | 1 | 2009 | 50 | 0.300 |
Why?
| | Cardiac Output | 3 | 2023 | 179 | 0.300 |
Why?
| | Safety | 1 | 2011 | 355 | 0.290 |
Why?
| | Cannabis | 1 | 2016 | 509 | 0.290 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 84 | 0.290 |
Why?
| | Hospitals, Urban | 1 | 2009 | 144 | 0.290 |
Why?
| | Automobile Driving | 1 | 2011 | 155 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2516 | 0.290 |
Why?
| | Pulsatile Flow | 2 | 2018 | 55 | 0.280 |
Why?
| | Mastitis | 1 | 2007 | 6 | 0.270 |
Why?
| | Counseling | 1 | 2011 | 400 | 0.270 |
Why?
| | Vascular Remodeling | 2 | 2021 | 204 | 0.270 |
Why?
| | Registries | 6 | 2021 | 2382 | 0.270 |
Why?
| | Antiviral Agents | 2 | 2025 | 767 | 0.260 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1487 | 0.260 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 68 | 0.260 |
Why?
| | Puerperal Disorders | 1 | 2007 | 37 | 0.260 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5389 | 0.260 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 336 | 0.260 |
Why?
| | Cytomegalovirus | 2 | 2025 | 168 | 0.260 |
Why?
| | Coronary Disease | 1 | 2009 | 381 | 0.260 |
Why?
| | Environment | 1 | 2009 | 305 | 0.250 |
Why?
| | Length of Stay | 2 | 2009 | 1335 | 0.250 |
Why?
| | Retrospective Studies | 14 | 2025 | 17009 | 0.240 |
Why?
| | Prospective Studies | 10 | 2021 | 7970 | 0.240 |
Why?
| | Diastole | 2 | 2018 | 141 | 0.240 |
Why?
| | Troponin I | 2 | 2019 | 72 | 0.230 |
Why?
| | HIV Infections | 1 | 2020 | 3079 | 0.220 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2025 | 34 | 0.220 |
Why?
| | Inpatients | 1 | 2009 | 542 | 0.220 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 27 | 0.220 |
Why?
| | Methyltransferases | 1 | 2025 | 74 | 0.210 |
Why?
| | Quality of Health Care | 1 | 2009 | 688 | 0.210 |
Why?
| | Biomarkers | 4 | 2026 | 4254 | 0.210 |
Why?
| | Double-Blind Method | 2 | 2026 | 2025 | 0.210 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 206 | 0.200 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 8 | 0.200 |
Why?
| | Prognosis | 6 | 2025 | 4278 | 0.200 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 195 | 0.200 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 33 | 0.190 |
Why?
| | Quality of Life | 6 | 2024 | 3166 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2143 | 0.190 |
Why?
| | MicroRNAs | 2 | 2022 | 700 | 0.190 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 243 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 41 | 0.190 |
Why?
| | Perioperative Care | 2 | 2017 | 230 | 0.190 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 46 | 0.190 |
Why?
| | Preoperative Care | 2 | 2017 | 379 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1559 | 0.190 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.180 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 114 | 0.180 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 442 | 0.180 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.180 |
Why?
| | Patient Transfer | 2 | 2019 | 206 | 0.180 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 13 | 0.180 |
Why?
| | Cohort Studies | 6 | 2023 | 5935 | 0.180 |
Why?
| | Succinic Acid | 2 | 2019 | 42 | 0.180 |
Why?
| | Triage | 1 | 2024 | 249 | 0.170 |
Why?
| | Hospitalization | 4 | 2024 | 2424 | 0.170 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 118 | 0.170 |
Why?
| | Recurrence | 2 | 2025 | 1134 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 21 | 0.170 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 219 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Carrier Proteins | 2 | 2022 | 736 | 0.170 |
Why?
| | Mice | 13 | 2025 | 18329 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1254 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 120 | 0.160 |
Why?
| | Muscle Proteins | 1 | 2022 | 244 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2022 | 3592 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 454 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1715 | 0.160 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1208 | 0.150 |
Why?
| | Transcriptome | 3 | 2025 | 1044 | 0.150 |
Why?
| | Animals | 17 | 2026 | 38030 | 0.150 |
Why?
| | HIV | 1 | 2020 | 248 | 0.150 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 137 | 0.150 |
Why?
| | Disease Progression | 2 | 2018 | 2840 | 0.150 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2917 | 0.140 |
Why?
| | Aortic Valve | 1 | 2022 | 360 | 0.140 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 297 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2020 | 255 | 0.140 |
Why?
| | Exercise Test | 4 | 2023 | 634 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 375 | 0.140 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 194 | 0.140 |
Why?
| | United States | 9 | 2023 | 15876 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2926 | 0.140 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.130 |
Why?
| | Rats | 6 | 2026 | 5592 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 186 | 0.130 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 276 | 0.130 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 358 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 261 | 0.130 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 16 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 4085 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 272 | 0.130 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 18 | 0.120 |
Why?
| | ErbB Receptors | 1 | 2020 | 627 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 164 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 627 | 0.120 |
Why?
| | Pilot Projects | 3 | 2019 | 1867 | 0.120 |
Why?
| | Histone Deacetylases | 1 | 2018 | 210 | 0.120 |
Why?
| | Self Care | 1 | 2019 | 388 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 278 | 0.120 |
Why?
| | Brain | 2 | 2018 | 2930 | 0.120 |
Why?
| | Eligibility Determination | 1 | 2016 | 68 | 0.120 |
Why?
| | Time Factors | 5 | 2024 | 7155 | 0.120 |
Why?
| | Polypharmacy | 1 | 2017 | 92 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2017 | 94 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 266 | 0.120 |
Why?
| | Anesthetics | 1 | 2017 | 99 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 65 | 0.120 |
Why?
| | Drug Interactions | 1 | 2017 | 397 | 0.120 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 23 | 0.120 |
Why?
| | Prosthesis Design | 3 | 2014 | 354 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 529 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 93 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2021 | 2048 | 0.120 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 427 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1050 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 323 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1782 | 0.110 |
Why?
| | Phosphorylation | 3 | 2019 | 1732 | 0.110 |
Why?
| | Tacrolimus | 1 | 2016 | 196 | 0.110 |
Why?
| | Consensus | 3 | 2023 | 488 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 288 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 110 | 0.110 |
Why?
| | Viscosity | 1 | 2015 | 90 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2009 | 1027 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 50 | 0.110 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1322 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2015 | 121 | 0.110 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 163 | 0.100 |
Why?
| | Health Status | 1 | 2019 | 833 | 0.100 |
Why?
| | Attitude to Health | 1 | 2017 | 434 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 404 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 741 | 0.100 |
Why?
| | Risk Factors | 5 | 2025 | 10699 | 0.100 |
Why?
| | Systole | 1 | 2014 | 178 | 0.100 |
Why?
| | Hip Prosthesis | 1 | 2014 | 42 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1379 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 64 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1422 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2870 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1495 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2134 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 822 | 0.100 |
Why?
| | Patient Selection | 2 | 2017 | 719 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2025 | 2916 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 597 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2016 | 250 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2014 | 268 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2017 | 777 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1285 | 0.090 |
Why?
| | Graft Survival | 2 | 2025 | 526 | 0.090 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 37 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2025 | 3119 | 0.090 |
Why?
| | Young Adult | 6 | 2019 | 13990 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1075 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2016 | 748 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2026 | 8243 | 0.080 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1182 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3403 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2026 | 2525 | 0.080 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 82 | 0.080 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 61 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 964 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2603 | 0.080 |
Why?
| | Connectin | 2 | 2022 | 42 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 177 | 0.080 |
Why?
| | Endpoint Determination | 2 | 2020 | 83 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 974 | 0.080 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 198 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1983 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 22 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 221 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1254 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 157 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 250 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 1646 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 85 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1460 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2022 | 4146 | 0.070 |
Why?
| | Anticoagulants | 1 | 2014 | 721 | 0.070 |
Why?
| | Disease Management | 2 | 2025 | 643 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1409 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2193 | 0.070 |
Why?
| | Ultrasonography | 1 | 2012 | 768 | 0.070 |
Why?
| | Europe | 2 | 2020 | 412 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4556 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1739 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 136 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 380 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5988 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 729 | 0.060 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 557 | 0.060 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 413 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 228 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 287 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2023 | 940 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2359 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 516 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 425 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 282 | 0.060 |
Why?
| | Benzoxazoles | 1 | 2024 | 20 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2024 | 109 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 557 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 198 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1833 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 42 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 48 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2061 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 847 | 0.050 |
Why?
| | Travel | 1 | 2023 | 136 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 138 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 96 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 87 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2026 | 698 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 38 | 0.050 |
Why?
| | Up-Regulation | 1 | 2025 | 851 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1347 | 0.040 |
Why?
| | Thiophenes | 1 | 2022 | 128 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5813 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 64 | 0.040 |
Why?
| | Calcium Channels | 1 | 2022 | 154 | 0.040 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 228 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 5221 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 322 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 151 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 28 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.040 |
Why?
| | Adolescent | 4 | 2019 | 22281 | 0.040 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 16 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 62 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 402 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1812 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 160 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2815 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 172 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 151 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 744 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 139 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 2088 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 196 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 63 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 498 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 126 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 460 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 66 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 621 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 104 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 946 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 355 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 197 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 459 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 205 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 242 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 322 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 346 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 519 | 0.030 |
Why?
| | Pyridines | 1 | 2022 | 605 | 0.030 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.030 |
Why?
| | Internship and Residency | 1 | 2009 | 1255 | 0.030 |
Why?
| | Fatty Acids | 1 | 2021 | 450 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2021 | 724 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 94 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.030 |
Why?
| | Myosins | 1 | 2018 | 136 | 0.030 |
Why?
| | Lysine | 1 | 2019 | 302 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 528 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 455 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 64 | 0.030 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 13 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 878 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Fibroblasts | 1 | 2022 | 1032 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 12 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 12 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 37 | 0.030 |
Why?
| | Papio | 1 | 2017 | 85 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 405 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 154 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6021 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 440 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 424 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 24 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 487 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 220 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 66 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 194 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 905 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 152 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 252 | 0.030 |
Why?
| | Actins | 1 | 2018 | 422 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 824 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 390 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 513 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 452 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2879 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1382 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 549 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 847 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2111 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1087 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3857 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2182 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 201 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 776 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 53 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1054 | 0.020 |
Why?
| | Action Potentials | 1 | 2017 | 506 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.020 |
Why?
| | Warfarin | 1 | 2014 | 170 | 0.020 |
Why?
| | Reoperation | 1 | 2016 | 629 | 0.020 |
Why?
| | Models, Biological | 1 | 2021 | 1820 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 863 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 243 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 512 | 0.020 |
Why?
| | Creatine | 1 | 2013 | 63 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2016 | 350 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1191 | 0.020 |
Why?
| | Glutamine | 1 | 2013 | 109 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1332 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11774 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 401 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 628 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1834 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 171 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 561 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 251 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2829 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 361 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1533 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 302 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3157 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 963 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 977 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2096 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 353 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3313 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1046 | 0.020 |
Why?
| | Child | 2 | 2019 | 22537 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 569 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 758 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10022 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 354 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1241 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|